Recent Advances in Atopic Dermatitis Treatments: Topicals, Orals, Biologics, and Emerging Pathways

Conclusions

• Topical therapy for atopic dermatitis and chronic hand eczema is expanding rapidly, with several new agents showing strong efficacy, fast itch relief, and generally low systemic exposure.
• Delgocitinib appears to be a breakthrough for chronic hand eczema because it is the first FDA-approved treatment for this condition and shows sustained improvements in severity, itch, pain, and quality of life.
• Ruxolitinib cream also demonstrates meaningful benefit in chronic hand eczema without atopic dermatitis, with more than half of patients reaching clear or almost clear skin by 16 weeks.
• Difamilast and other topical PDE4 inhibitors provide effective, age-appropriate options for mild to moderate atopic dermatitis with good tolerability.
• Oral JAK inhibitors such as abrocitinib and upadacitinib show durable long-term efficacy, and available safety analyses do not suggest major cumulative new safety signals overall.
• Safety risk with oral JAK inhibitors may be more pronounced in older adults and at higher doses, supporting age- and dose-aware treatment decisions.
• STAT6 is emerging as a promising upstream oral target because blocking it may suppress IL-4/IL-13-driven Th2 inflammation while preserving a more selective mechanism than broader JAK inhibition.
• KT-621 has shown strong early pharmacologic activity with STAT6 degradation and biomarker reduction, and it is advancing in clinical trials.
• Biologic therapies continue to show durable benefit across longer follow-up and younger age groups, with evidence that treating atopic dermatitis can improve growth, quality of life, and caregiver burden.
• Lebrikizumab appears capable of maintaining control with less frequent every-8-week dosing after response, which could reduce treatment burden.
• Nemolizumab shows sustained benefit in pediatric atopic dermatitis and pruritus, improving itch, rash, and quality of life with acceptable safety even in younger children.
• Tralokinumab can provide long-term disease control for difficult areas such as head and neck atopic dermatitis, with benefits persisting for years.
• Targeting the OX40/OX40L pathway may offer broader and more durable immune modulation than downstream cytokine blockade by affecting multiple T-cell populations and memory responses.
• Amlitelimab, an anti-OX40L therapy, has produced positive phase 3 efficacy signals with a safety profile that appears comparable to placebo so far.
• Rocatinlimab development has been discontinued because of safety concerns, showing that not all immune-targeted approaches will prove viable.
• Overall, the field of atopic dermatitis and chronic hand eczema treatment is moving toward more precise, durable, and age-expanding options, with many additional therapies in development.